CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma — Stella

Home/Peripheral T Cell Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to Peripheral T Cell Lymphoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina

Key details

Phase

Safety & dosing

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment target

~20 participants

Started

September 2019

Primary completion

February 2028

Age range

18 Years – 99 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.